Trial Profile
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Savolitinib (Primary)
- Indications Renal cell carcinoma
- Focus Proof of concept; Therapeutic Use
- Sponsors AstraZeneca
- 18 Apr 2018 Results (n=84) presented at the 109th Annual Meeting of the American Association for Cancer Research.
- 18 Feb 2017 Preliminary results (Cut off 27 June 2016) presented at the 2017 Genitourinary Cancers Symposium
- 14 Feb 2017 Results from this trial will be presented at the 2017 Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO-GU), according to a Chi-Med media release.